Website
N/ATelephone
61.7.3152.3200
Address
Suite 302, Level 3 9 Sherwood Road Toowong Tower Toowong, Queensland (QLD) 4066
Description
Anteris Technologies Ltd. is a structural heart company, which engages in research, develops, commercializes, and distributes medical technologies and devices. It operates through the following geographical segments: Australia, United States, and Switzerland. It manufactures, distributes, and sells ADAPT and DurAVR regenerative tissue products, and researches and develops regenerative medicine and immunotherapies. The company was founded on June 23, 1999 and is headquartered in Toowong, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 15.49 - 23.93
Trade Value (12mth)
AU$65,240.00
1 week
-7.86%
1 month
-13.68%
YTD
-17.32%
1 year
-25.9%
All time high
186.88
EPS 3 yr Growth
67.000%
EBITDA Margin
%
Operating Cashflow
-$51m
Free Cash Flow Return
-234.70%
ROIC
-307.30%
Interest Coverage
-160.10
Quick Ratio
2.50
Shares on Issue (Fully Dilluted)
16m
HALO Sector
Healthcare
Next Company Report Date
27-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
24 July 24 |
Capital Raise
×
Capital Raise |
24 July 24 |
Proposed issue of securities - AVR
×
Proposed issue of securities - AVR |
22 July 24 |
Pause in trading
×
Pause in trading |
22 July 24 |
Trading Halt
×
Trading Halt |
01 July 24 |
Anteris and v2vmedtech Announce Concept Lock for VClip
×
Anteris and v2vmedtech Announce Concept Lock for VClip |
25 June 24 |
Notification regarding unquoted securities - AVR
×
Notification regarding unquoted securities - AVR |
25 June 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
20 June 24 |
FIH Data Confirms Optimal Valve Positioning with ComASUR
×
FIH Data Confirms Optimal Valve Positioning with ComASUR |
18 June 24 |
Update on Pivotal Trial Submission
×
Update on Pivotal Trial Submission |
13 June 24 |
Update on DurAVR Valve-in-Valve Experience
×
Update on DurAVR Valve-in-Valve Experience |
11 June 24 |
Data Update on First-in-Human Study of DurAVR at NY Valves
×
Data Update on First-in-Human Study of DurAVR at NY Valves |
31 May 24 |
Notification of cessation of securities - AVR
×
Notification of cessation of securities - AVR |
29 May 24 |
AGM Chairman and CEO Presentation
×
AGM Chairman and CEO Presentation |
29 May 24 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
28 May 24 |
Notice of Annual General Meeting - Withdrawal of Resolution
×
Notice of Annual General Meeting - Withdrawal of Resolution |
15 May 24 |
First in Human TAVR in TAVR in SAVR using DurAVR
×
First in Human TAVR in TAVR in SAVR using DurAVR |
13 May 24 |
Application for quotation of securities - AVR
×
Application for quotation of securities - AVR |
13 May 24 |
Cleansing Notice
×
Cleansing Notice |
02 May 24 |
Notification regarding unquoted securities - AVR
×
Notification regarding unquoted securities - AVR |
29 April 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
18 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
18 April 24 |
Cleansing Notice
×
Cleansing Notice |
17 April 24 |
Application for quotation of securities - AVR
×
Application for quotation of securities - AVR |
15 April 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
15 April 24 |
Corporate Governance Statement and Appendix 4G
×
Corporate Governance Statement and Appendix 4G |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.